Cargando…

Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yige, Yang, Jie, Li, Yingbo, Luo, Jing, Sun, Jiemei, Li, Daoshuang, Wang, Yuchen, Wang, Kai, Yang, Lili, Wu, Lina, Sun, Xilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717478/
https://www.ncbi.nlm.nih.gov/pubmed/36457016
http://dx.doi.org/10.1186/s12943-022-01681-y
_version_ 1784842910161698816
author Sun, Yige
Yang, Jie
Li, Yingbo
Luo, Jing
Sun, Jiemei
Li, Daoshuang
Wang, Yuchen
Wang, Kai
Yang, Lili
Wu, Lina
Sun, Xilin
author_facet Sun, Yige
Yang, Jie
Li, Yingbo
Luo, Jing
Sun, Jiemei
Li, Daoshuang
Wang, Yuchen
Wang, Kai
Yang, Lili
Wu, Lina
Sun, Xilin
author_sort Sun, Yige
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC. METHODS: We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens. RESULTS: INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by (19)F magnetic resonance imaging ((19)F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens. CONCLUSIONS: These results demonstrated high anti-MET/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01681-y.
format Online
Article
Text
id pubmed-9717478
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97174782022-12-03 Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC Sun, Yige Yang, Jie Li, Yingbo Luo, Jing Sun, Jiemei Li, Daoshuang Wang, Yuchen Wang, Kai Yang, Lili Wu, Lina Sun, Xilin Mol Cancer Research BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC. METHODS: We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens. RESULTS: INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by (19)F magnetic resonance imaging ((19)F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens. CONCLUSIONS: These results demonstrated high anti-MET/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01681-y. BioMed Central 2022-12-01 /pmc/articles/PMC9717478/ /pubmed/36457016 http://dx.doi.org/10.1186/s12943-022-01681-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Yige
Yang, Jie
Li, Yingbo
Luo, Jing
Sun, Jiemei
Li, Daoshuang
Wang, Yuchen
Wang, Kai
Yang, Lili
Wu, Lina
Sun, Xilin
Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
title Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
title_full Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
title_fullStr Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
title_full_unstemmed Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
title_short Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
title_sort single low-dose inc280-loaded theranostic nanoparticles achieve multirooted delivery for met-targeted primary and liver metastatic nsclc
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717478/
https://www.ncbi.nlm.nih.gov/pubmed/36457016
http://dx.doi.org/10.1186/s12943-022-01681-y
work_keys_str_mv AT sunyige singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT yangjie singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT liyingbo singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT luojing singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT sunjiemei singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT lidaoshuang singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT wangyuchen singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT wangkai singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT yanglili singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT wulina singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc
AT sunxilin singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc